The study inclusion criteria were: (1) an age of ≥18 years; (2) biopsy-confirmed EP (i.e., psoriasis affecting ≥80% of the body surface area [BSA] with inflammatory erythema at baseline) or PP diagnosed based on the 2017 European Consensus Statement [3]; and (3) treatment with an IL-17 or IL-23 inhibitor. Here, IL37 is linked to psoriasis.